Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules

Author(s): Gianfranco Calogiuri, Eustachio Nettis, Elisabetta Di Leo, Caterina Foti, Antonio Ferrannini, Lavjay Butani

Journal Name: Inflammation & Allergy - Drug Targets (Discontinued)
(Formerly Current Drug Targets - Inflammation & Allergy)

Volume 12 , Issue 1 , 2013


Allopurinol, an analog of hypoxanthine has been worldwide used for the treatment of hyperuricemia and gout for over 40 years. Unfortunately some patients assuming this medication have developed hypersensitivity reactions ranging from mild cutaneous eruption to more severe clinical manifestations such as allopurinol hypersensitivity syndrome or Steven-Johnson syndrome and lethal toxic epidermal necrolysis. Various strategies of slow desensitization have been elaborated to reintroduce allopurinol in a part of these patients, mainly patients affected by mild skin reactions as fixed drug eruption or exanthema. However, several new uricosuric therapies have been recently introduced. Actually drugs as recombinant urate oxidase and febuxostat are under post-marketing surveillance to control potential adverse effects related to their immunogenicity even.

Keywords: Allopurinol, anakinra, desensitization, febuxostat, hypersensitivity, rasburicase, hypoxanthine, gout, TNF-alpha, hyperuricemia

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 21 January, 2013
Page: [19 - 28]
Pages: 10
DOI: 10.2174/1871528111312010004

Article Metrics

PDF: 72